Freehills lawyer new VP of global IP group
Wednesday, 24 April, 2002
Adam Liberman, a partner at law firm Freehills, has been appointed vice-president of the Licensing Executives Society International (LESI), a global intellectual property organisations.
LESI regularly advises policy-making groups like the World Trade Organisation, the International Chamber of Commerce, and the UN International Development Organisation.
"In the Australian context, this appointment will provide me with greater credibility to promote the importance of IP to Australian business," Liberman said. "That importance in my view has not yet been fully grasped."
LESI is the largest professional association in the world, and deals with IP issues. It consists of 28 national and regional licensing executive societies, and has over 11,000 members from 84 countries.
The focus of a LES is the business application of IP rights. Its members include CEOs, business development managers, entrepreneurs, venture capitalists, scientists, engineers, academics, lawyers, patent attorneys, government officials, accountants and others from large, medium and small enterprises, independent firms, universities and R&D organisations, government organisations and consulting firms.
The focus of LES education and networking activities is the business application of intellectual property rights through such means as licensing, technology transfer, intellectual asset management and venture capital investment.
"I'm very honoured to be given this role, and intend to promote the importance of IP as a business asset not only in Australia, but in the Asia-Pacific region," Liberman said.
Plug-and-play test evaluates T cell immunotherapy effectiveness
The plug-and-play test enables real-time monitoring of T cells that have been engineered to fight...
Common heart medicine may be causing depression
Beta blockers are unlikely to be needed for heart attack patients who have a normal pumping...
CRISPR molecular scissors can introduce genetic defects
CRISPR molecular scissors have the potential to revolutionise the treatment of genetic diseases,...